Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target brain neurons that control ...

Eli Lilly & Co has experienced a significant stock price decline of 18.64% over the past week, largely due to disappointing ...